An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Precision BioSciences, Inc. (Nasdaq: DTIL) has announced its participation in the H.C. Wainwright Global Investment Conference on May 24, 2022. The company will also publish its financial results for the first quarter of 2022 and provide a business update on May 9, 2022. The conference presentation will be available on-demand starting at 7:00 AM ET. Precision BioSciences is focused on developing innovative CAR T therapies and gene editing platforms using its proprietary ARCUS technology.
Positive
Participation in the H.C. Wainwright Global Investment Conference, enhancing visibility among investors.
Upcoming financial results update expected on May 9, 2022.
Negative
None.
Company to Participate in the H.C. Wainwright Global Investment Conference on May 24, 2022
DURHAM, N.C.--(BUSINESS WIRE)--
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the first quarter 2022 and provide a business update on May 9, 2022. Precision BioSciences also announced that Michael Amoroso, Chief Executive Officer will participate in the H.C. Wainwright Global Investment Conference on May 24, 2022.
Details for the virtual presentation are below:
H.C. Wainwright Global Investment Conference Date: Tuesday, May 24, 2022 Time: On-demand session available at 7:00 AM ET
A live webcast of the presentation will be accessible on the Company’s website in the Investors section under Events & Presentations: https://investor.precisionbiosciences.com/events-and-presentations. An archived replay of the webcast will be available for approximately 30 days.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene editing therapy candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit www.precisionbiosciences.com.
